A comatose patient arrived at the emergency room with apnea and in shock after a grand mal seizure. A maculopapular rash, not initially observed, led to a diagnosis of cutaneous mastocytosis. Degranulation of the mast cells with massive histamine release had resulted in cardiovascular collapse.
A comatose patient arrived at the emergency room with apnea and in shock after a grand mal seizure. A maculopapular rash, not initially observed, led to a diagnosis of cutaneous mastocytosis. Degranulation of the mast cells with massive histamine release had resulted in cardiovascular collapse.
The authors follow a detailed report of this case history with a discussion of the diagnosis and treatment of the acute systemic stage of this potentially life-threatening illness.
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True dermat ologic emergencies are exceedingly rare in the day-to-day practice of emergency medicine. The following case is presented to alert th e clinician to the existence of one such potentially life-threatening disease masquerading as a routine medical problem. In this case, massive histamine release from a dermatologic manifestation of a systemic disease-acute systemic mastocytosis-took the form of seizure, shock, and coma.
Report of case
A 32-year-old woman was at home watching television with her husband when she complained of "not feeling well," being "warm all over," and experiencing vague abdominal pain. Her husband, sensing that his wife was acutely ill, called an ambulance. Shortly thereafter, the patient lost consciousness and had a grand mal seizure lasting about 1 minute. The patient arrived at the hospital emergency department 7 minutes later. Examination revealed the patient to be cyanotic, apneic, incontinent of urine and feces , and unresponsive to deep painful stimuli. Her temperature was 37°C, her pulse was 140 beats per minute, and her blood pressure was unmeasurable. The pupils were 5 mm in diameter and sluggishly reactive bilaterally. Advanced cardiac life support and a coma protocol were initiated. The patient was intubated and given four ampules of naloxone, 50 g of dextrose and water, dopamine, and lactated Ringer's solution. Approximately 10 minutes after initiation of resuscitation, the patient's blood pressure began to rise; she regained consciousness and no longer needed respiratory support.
Results of the preliminary blood workup were totally unremarkable except for preintubation blood gases that showed a pH of7.32, a PC0 2 of90 torr, and a P0 2 of 66 torr while the patient was being manually ventilated under high-flow oxygen. The patient's history was significant for a seizure during childbirth 14 years previously and for a complaint of palpitations controlled by nadolol 6 months before this hospital admission. The patient was not currently taking medications nor did she have any family history of a seizure disorder or drug use.
The patient was transferred to the radiology departr ment for a computed tomography CCT) scan of the head. It was observed at that time that she had a diffuse brown to red maculopapular rash involving the face, the anterior and posterior aspects of the thorax, and all extremities, but sparing the palms and soles. Her husband stated that this rash had been present for many months; that it was transient, lasting days to weeks at a time; but that it never seemed to have bothered her except for cosmetic reasons.
After admission, the patient underwent multiple diagnostic tests. Computed tomography and magnetic resonance imaging of the head produced normal results as did serum and urine toxicology screens. Cardiac monitoring failed to reveal any arrhythmia, and results of waking electroencephalograms (EEGs) were normal. The sleep EEG showed a I-second episode of grade III dysrhythmia in the left hemisphere, suggesting a lowered threshold for seizures with a focus in the left temporal region. During the course of admission, a dermatology consultation was obtained and a biopsy was performed on one of the maculopapular lesions ( Figure  1 ). The consultant's clinical impression of diffuse mastocytosis was confirmed by the biopsy.
The patient had an uncomplicated hospital stay. She was treated with an HI-blocker (diphenhydramine) and an H 2 -antagonist (cimetidine). The patient was given an epinephrine kit for emergency home use, and her entire family was instructed regarding its use. She was also instructed to abstain from over-the-counter medications as they could be potential triggering agents for her disease. She has had several minor symptomatic episodes that have responded well to increases in her medications. Discussion Mastocytosis, or urticaria pigmentosa, is an uncommon disease characterized by abnormal mast cell proliferation. Clinical signs and symptoms reflect the acute elevation of released mast cell derivatives and mediators, primarily histamine and heparin, which are contained within the mast cell itself The mast cell hyperplasia is usually localized in the dermal layers but has a significant potential for systemic infiltrates into bone, spleen, liver, and blood and lymphatic systems. Mastocytosis was first described by NettlE~ship in 1869. 1 Mast cells are derived from bone marrow stem cells. They then migrate to target organs-such as skin, connective tissues, and the reticuloendothelial system-where they mature into fully granulated cells. They are thought to playa primary role in immediate and delayed hypersensitivity reactions. Histamines and other peptidases are released when 19E receptors on the cell's surface membrane bind with various internal or external antigens. Degranulation of the mast cells is also often associated with drug ingestion, external toxins such as venomous bites, or other noxious stimuli. 2 Mast cell mediators produce their effects either at their site of production or remotely through the blood and lymphatic systems. The mediators are Case report • Kamajian and Felix of three types: granule-associated substances such as histamine and heparin, lipid-derived mediators such as leukotrienes and prostaglandins, and cytokines such as interleukins. 3 Classification of mastocytosis has, in the past, been based on dissemination of the mast cells into cutaneous or systemic invasive forms and then further subdivided into benign or malignant outcomes. Most recently, four categories proposed by Travis and colleagues 2 and revised by Metcalfe at the National Institutes of Health 4 have been used. most fulminant form of mastocytosis, with a mean survival ofless then 6 months from time of diagnosis. The fourth category is lymphadenopathic mastocytosis with eosinophilia. This form is also aggressive and has a poor prognosis.
The onset of mastocytosis occurs before the age of 2 years in 50% of all patients. Among children, 50% of all cases with isolated urticaria pigmentosa resolve by adulthood. 5 When death does occur from disease in any of these classifications, it is usually secondary to anaphylaxis, hemorrhage, leukemia, or cachexia.
The typical patient may have any or all of the protean effects of mast cell degranulation. The reddish brown maculopapular lesions of urtIcaria pigmentosa are present in 90% of class I mastocytosis and in less then 50% of class II through IV disease. Degranulation of the mast cells with associated histamine release can occur after direct physical contact such as rubbing and scratching. The production of an acute localized urticaria by rubbing is called Darier's sign and may be used to demonstrate the classic form of this disease.
Predominant signs and symptoms include urticaria; flushing; headache; and gastrointestinal complaints such as nausea, vomiting, and diarrhea ( Table 2 ).6 Gastrointestinal symptoms are followed by malabsorption in 30% of They are based on prognosis and associated hematologic disorders and clinical presentation ( Table 1) .
The prognosis is good only in the first category-indolent systemic mastocytosis. This indolent systemic entity may be seen with skin lesions only or with systemic multiorgan involvement with an inactive or benign course. The second category is mastocytosis associated with hematologic disorders. The outcome is determined by the prognosis of the associated hematologic disorder:
patients. Hepatic and splenic involvement results in fibrosis with portal hypertension and ascites. An increase in bleeding tendencies from heparin release-in which heparin acts as a local anticoagulant-exaggerates preexisting microscopic gastric bleeding, epistaxis, or stroke. A correlation also exists between plasma histamine levels and elevated gastric acidity.7 Additional symptoms, such as palpitations and tachyarrhythmias, frequently occur ( Table 3) . 6 Because symptoms are related to the quantity and acuteness of the histamine and associated peptidases released, the entire clinical range of the allergic reaction spectrum from simple urticaria to anaphylaxis and death may be observed.
The most definitive criterion for diagnosis of mastocytosis is histologic demonstration of mast cell hyperplasia and infiltrates on biopsy by Giemsa or toluidine staining. 2 The presence of these lesions in extracutaneous ti~sues confirms the degree of systemic involvement. Clinically, the cutaneous lesions may appear in a wide range of diffuse or solitary maculopapular, nodular, oroccasionally-vesicular eruptions (Figure 2 ).
Serum and urinary histamine levels may also be measured. Urine must be accumulated for 24 hours and both serum and urinary tests require radioimmunoassay. Plasma histamine values may be useful in followIDg the clinical course of the disease.
Symptoms related to bone involvement have been reported in 10% to 30% of patients. Bone pain is often the primary complaint; radiologically, 70% of patients have lesions that appear as osteoporosis and pathologic fractures. Of the lesions examined by biopsy specimen, about one fourth are mastocytomas. 8 Bone marrow biopsy is often the sole means of diagnosis of systemic disease that has not shown the classic skin lesions of urticaria pigmentosa. Bone marrow is the most common extracutaneous site for establishing a diagnosis by biopsy. These focal areas of mast cell hyperplasia usually consist of nodular collections of fusiform mast cells and paratrabecular infiltrates associated with lymphocytes and eosinophils.
The clinical manifestations of mastocytosis are caused by the release of mast cell mediators, such as histamine, and by the mechanical conseCase report· Kamajian and Felix .PUVA
• Chemotherapy
• Splenectomy
• Interferon alfa-2b
quences of the existence of a large volume of proliferating celis, resulting often in fibrosis and end organ damage. At present there is no cure for mastocytosis, and the treatment is often limited to treatment of symptoms (Table 4) . 4 . HI antihistamines, such as hydroxyzine and diphenhydramine, are administered for flushing and pruritus. H2 antihistamines, such as ranitidine and cimetidine, are used to treat gastric ulcer disease. 9 Cromolyn sodium, a mast cell stabilizer, is offered for diarrhea and abdominal pain, headache, and bone pain. More severe cases of mastocytosis have responded to low-dose steroids. Aspirin and other nonsteroidal anti-inflammatory agents have been successful in treating recurrent flushing. Methoxsalen and longwave ultraviolet radiation (PUVA) have been helpful. Splenectomy has increased survival in patients with type II and type IV disease. IO Chemotherapy may also have a role. A case has been reported in which interferon a-2b was used with excellent results to treat a patient with class II mastocytosis.
11 Epinephrine, fluid, and vasopressors remain the treatment of choice for acute anaphylaxis.
Comment
The case history presented here demonstrates the need to explore all potential causes of seizure, coma, and shock. In the patient described here, a syncopal episode followed by seizure, coma, and shock probably represented a sudden hypotensive episode related to mast cell degranulation and associated histamine release producing acute anaphylaxis. An almost incidentally observed skin rash, later diagnosed as cutaneous mastocytosis (urticaria pigmentosa), was the probable cause of this n ear-fatal event. Early recognition and treatment of this condition can help to avoid these lifethreatening complications of acute systemic mastocytosis.
